Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,269 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic model for relapsed/refractory transplant-ineligible diffuse large B-cell lymphoma utilizing the lymphocyte-to-monocyte ratio.
Ide D, Fujino T, Kobayashi T, Egashira A, Miyashita A, Mizuhara K, Isa R, Tsukamoto T, Mizutani S, Uchiyama H, Kaneko H, Uoshima N, Kawata E, Taniwaki M, Shimura Y, Kuroda J. Ide D, et al. Among authors: tsukamoto t. Int J Hematol. 2024 Mar 16. doi: 10.1007/s12185-024-03750-y. Online ahead of print. Int J Hematol. 2024. PMID: 38492199
Detection of chromosomal abnormalities by G-banding and prognostic impact in follicular lymphoma in the rituximab era.
Tsukamoto T, Kiyota M, Kawata E, Uoshima N, Tatekawa S, Chinen Y, Nagoshi H, Mizutani S, Shimura Y, Yamamoto-Sugitani M, Kobayashi T, Horiike S, Yasukawa S, Yanagisawa A, Taniwaki M, Kuroda J. Tsukamoto T, et al. Int J Hematol. 2017 May;105(5):658-667. doi: 10.1007/s12185-016-2166-0. Epub 2016 Dec 19. Int J Hematol. 2017. PMID: 27995457
Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma.
Isa R, Uoshima N, Takahashi R, Nakano-Akamatsu S, Kawata E, Kaneko H, Shimura K, Kamitsuji Y, Takimoto-Shimomura T, Mizutani S, Chinen Y, Ohshiro M, Fujino T, Kawaji Y, Uchiyama H, Sasaki N, Tsukamoto T, Shimura Y, Kobayashi T, Taniwaki M, Kuroda J; Kyoto Clinical Hematology Study Group investigators. Isa R, et al. Among authors: tsukamoto t. Ann Hematol. 2020 Jan;99(1):137-145. doi: 10.1007/s00277-019-03859-9. Epub 2019 Nov 25. Ann Hematol. 2020. PMID: 31768675 Clinical Trial.
Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pilot prospective observational study.
Kawaji-Kanayama Y, Muramatsu A, Sasaki N, Shimura K, Kiyota M, Fuchida S, Isa R, Fujino T, Matsumura-Kimoto Y, Tsukamoto T, Chinen Y, Mizutani S, Nakao M, Kaneko H, Kawata E, Hirakawa K, Takahashi R, Shimazaki C, Uchiyama H, Uoshima N, Shimura Y, Kobayashi T, Taniwaki M, Kuroda J; Kyoto Clinical Hematology Study Group (KOTOSG) Investigators. Kawaji-Kanayama Y, et al. Among authors: tsukamoto t. Int J Hematol. 2022 Mar;115(3):350-362. doi: 10.1007/s12185-021-03262-z. Epub 2022 Jan 24. Int J Hematol. 2022. PMID: 35072907
Real-world practice-based prognostic model for higher-risk myelodysplastic syndromes treated with azacitidine monotherapy: The Kyoto prognostic scoring system.
Okamoto H, Inoue Y, Miyashita A, Kawaji-Kanayama Y, Chinen S, Fujino T, Tsukamoto T, Shimura Y, Mizutani S, Kaneko H, Kuwahara-Ota S, Fuchida SI, Nishiyama D, Hirakawa K, Uchiyama H, Uoshima N, Kawata E, Kuroda J; KOTOSG investigators. Okamoto H, et al. Among authors: tsukamoto t. Int J Hematol. 2023 Sep;118(3):323-332. doi: 10.1007/s12185-023-03627-6. Epub 2023 Jun 28. Int J Hematol. 2023. PMID: 37378717
Intravenous bortezomib for multiple myeloma that has progressed after subcutaneous bortezomib therapy.
Kuroda J, Mizutani S, Shimura Y, Maegawa S, Nagoshi H, Chinen Y, Tatekawa S, Tsukamoto T, Mizuno Y, Yamamoto-Sugitani M, Kobayashi T, Matsumoto Y, Horiike S, Taniwaki M. Kuroda J, et al. Among authors: tsukamoto t. Ann Hematol. 2015 Apr;94(4):687-9. doi: 10.1007/s00277-014-2214-x. Epub 2014 Sep 12. Ann Hematol. 2015. PMID: 25209844 No abstract available.
Chromosomal abnormality variation detected by G-banding is associated with prognosis of diffuse large B-cell lymphoma treated by R-CHOP-based therapy.
Mizuno Y, Tsukamoto T, Kawata E, Uoshima N, Uchiyama H, Yokota I, Maegawa S, Takimoto T, Tanba K, Matsumura-Kimoto Y, Kuwahara-Ota S, Fujibayashi Y, Yamamoto-Sugitani M, Chinen Y, Shimura Y, Horiike S, Taniwaki M, Kobayashi T, Kuroda J. Mizuno Y, et al. Among authors: tsukamoto t. Cancer Med. 2018 Mar;7(3):655-664. doi: 10.1002/cam4.1342. Epub 2018 Feb 23. Cancer Med. 2018. PMID: 29473332 Free PMC article.
A novel method of amplified fluorescent in situ hybridization for detection of chromosomal microdeletions in B cell lymphoma.
Mizuno Y, Chinen Y, Tsukamoto T, Takimoto-Shimomura T, Matsumura-Kimoto Y, Fujibayashi Y, Kuwahara-Ota S, Fujino T, Nishiyama D, Shimura Y, Kobayashi T, Horiike S, Taniwaki M, Kuroda J. Mizuno Y, et al. Among authors: tsukamoto t. Int J Hematol. 2019 May;109(5):593-602. doi: 10.1007/s12185-019-02617-x. Epub 2019 Mar 4. Int J Hematol. 2019. PMID: 30830578
Prediction of delayed platelet engraftment after autologous stem cell transplantation for B-cell non-Hodgkin lymphoma.
Yamaguchi J, Chinen Y, Takimoto-Shimomura T, Nagata H, Muramatsu A, Kuriyama K, Ohshiro M, Hirakawa Y, Iwai T, Uchiyama H, Uoshima N, Kaneko H, Nakao M, Tsukamoto T, Shimura Y, Kobayashi T, Horiike S, Yokota I, Kuroda J; KOTOSG Investigators. Yamaguchi J, et al. Among authors: tsukamoto t. Leuk Lymphoma. 2019 Dec;60(14):3434-3441. doi: 10.1080/10428194.2019.1636982. Epub 2019 Jul 18. Leuk Lymphoma. 2019. PMID: 31318305
2,269 results